State Street Corp. Amends Zentalis Pharma Stake Filing
Ticker: ZNTL · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1725160
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street Corp. still holds Zentalis Pharma shares, signaling continued institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Zentalis Pharmaceuticals Inc. common stock as of December 31, 2023. This filing updates their previous disclosure, showing their continued significant, though passive, investment in Zentalis. For investors, this means a large institutional holder maintains its position, which can signal confidence in the company's long-term prospects, but it doesn't suggest any active involvement in Zentalis's management or strategy.
Why It Matters
This filing confirms State Street Corporation's continued passive institutional ownership in Zentalis Pharmaceuticals, which can be a positive signal of long-term confidence for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing is a routine update from a passive institutional investor and does not indicate any immediate risks or changes in company operations.
Analyst Insight
A smart investor would note State Street's continued passive stake as a sign of institutional confidence, but recognize this filing doesn't signal any new strategic moves or significant changes in Zentalis's business outlook.
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Zentalis Pharmaceuticals, Inc. (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the date the SC 13G/A was filed
- 98943L107 (string) — the CUSIP number for Zentalis Pharmaceuticals Inc. common stock
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, indicating a change or update to a previous disclosure of beneficial ownership.
Who is the 'Reporting Person' in this filing?
The 'Reporting Person' is STATE STREET CORPORATION, a financial institution based in Boston, MA, as stated on the cover page and in the 'FILED BY' section.
What is the 'Subject Company' or 'Issuer' of the securities?
The 'Subject Company' or 'Issuer' is ZENTALIS PHARMACEUTICALS INC, a pharmaceutical preparations company with a business address in New York, NY.
What is the 'Date of Event Which Requires Filing of This Statement'?
The 'Date of Event Which Requires Filing of This Statement' is 12/31/2023, as specified on the cover page of the filing.
Under which rule is this Schedule 13G filed?
This Schedule 13G is filed under Rule 13D-1 (B), as indicated by the 'X' next to 'RULE 13D-1 (B)' on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding Zentalis Pharmaceuticals, Inc. (ZNTL).